Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools
RRMUT
1 other identifier
interventional
5
1 country
1
Brief Summary
- 1.Inclusion of 5 families Inclusions will be made by the clinical genetics department of the Rouen University Hospital (monocentric study) and will correspond to trios of parents + child with unexplained developmental abnormalities. The inclusion of patients will be integrated in routine care and will have as immediate benefit for the included families the extensive analysis of the proband and their parents' genomes by short and long read sequencing techniques, which represent the most comprehensive diagnostic tests for developmental diseases, and which are not currently routinely available. Inclusion in clinical genetics by clinicians accustomed to prescribing genome-wide analyses will allow clear and complete information to families. Collection of consents. The trio's DNA will already be available at the molecular genetics laboratory, and a new blood sample may be proposed if necessary. Collection of sperm from the father.
- 2.Identification of a large set of de novo mutations. Extraction of blood DNA and sending for sequencing of the complete genome to the National Centre for Research in Human Genomics (CNRGH, Evry), in the framework of a collaboration already initiated. Analysis of the sequencing data thanks to the already existing expertise in Rouen. Identification of about 40-120 de novo mutations per trio. At this stage: interpretation of the variations identified with the secondary objective of identifying the cause of the disease in children. Long read genomes will allow to phase the de novo variants to the paternal or to the maternal haplotype.
- 3.Search for de novo mutations in paternal sperm samples. Extraction of spermatic DNA. Design of a sequencing panel targeting the genetic variations identified in the different trios. Preparation of the libraries, targeted high throughput sequencing at great depth thanks to the techniques and equipment already operational. Specific search for the de novo variations identified in the probands (in 2.), with for each evaluation of (i) the presence of the variation in the sperm sample, (ii) the quantity of mosaicism, reflecting the proportion of carrier spermatozoa and therefore the risk of recurrence, (iii) the presence of my variation in the blood sample of both parents in deep sequencing.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 21, 2020
CompletedFirst Posted
Study publicly available on registry
September 25, 2020
CompletedStudy Start
First participant enrolled
February 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 12, 2022
CompletedApril 20, 2026
February 1, 2026
1.8 years
September 21, 2020
April 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of the patient's de novo mutations detectable in the father's sperm
Day 1
Secondary Outcomes (1)
Number of patients for whom molecular diagnosis has been obtained (cause of developmental disability identified) ≥1
Day 1
Study Arms (1)
Indication for a genome-wide analysis in the proband
EXPERIMENTALInterventions
genome-wide analyses will be done in patients and parents (father, mother)
Sperm analysis will be done in paternal samples
Eligibility Criteria
You may qualify if:
- Trio consisting of a child with a developmental disorder and both unaffected parents
- Absence of etiology after clinical expertise and genetic testing
- Indication of a genome-wide sequencing analysis
- Child from spontaneous pregnancy without ovulation stimulation treatment
- Availability of DNA blood samples
- Affiliation to a social insurance
- Patient or patient's legal representative who has read and understood the information letter and has signed the consent form
You may not qualify if:
- Lack of indication for a genome-wide analysis in the proband
- Etiology of the developmental disorder already identified
- Proband born after In-Vitro Fertilization
- Impossibility of non-invasive sperm collection from the father
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rouen University Hospital
Rouen, France
Related Publications (2)
Lecoquierre F, Drouot N, Coutant S, Quenez O, Fourneaux S, Jumeau F, Rives N, Charbonnier F, Derambure C, Boland A, Olaso R, Meyer V, Deleuze JF, Goldenberg A, Guerrot AM, Charbonnier C, Nicolas G. Parental germline mosaicism in genome-wide phased de novo variants: Recurrence risk assessment and implications for precision genetic counselling. PLoS Genet. 2025 Mar 31;21(3):e1011651. doi: 10.1371/journal.pgen.1011651. eCollection 2025 Mar.
PMID: 40163539RESULTLecoquierre F, Quenez O, Fourneaux S, Coutant S, Vezain M, Rolain M, Drouot N, Boland A, Olaso R, Meyer V, Deleuze JF, Dabbagh D, Gilles I, Gayet C, Saugier-Veber P, Goldenberg A, Guerrot AM, Nicolas G. High diagnostic potential of short and long read genome sequencing with transcriptome analysis in exome-negative developmental disorders. Hum Genet. 2023 Jun;142(6):773-783. doi: 10.1007/s00439-023-02553-1. Epub 2023 Apr 19.
PMID: 37076692RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
François LECOQUIERRE, MD
University Hospital, Rouen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 21, 2020
First Posted
September 25, 2020
Study Start
February 24, 2021
Primary Completion
December 12, 2022
Study Completion
December 12, 2022
Last Updated
April 20, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share